No Human Exposure Data
PEG-MGF
Also known as Pegylated mechano growth factor
At a glance
- What it is
- Sold for muscle and tendon repair. FDA found no human exposure data by any route.
- Evidence
- Practitioner experience onlyHow the tiers workFDA’s note on the withdrawn table is unambiguous: it has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration. Why this tier
- Half-life
- Not established in available literature
- Routes
- Subcutaneous, Intramuscular
- Category
- Growth hormone, Healing
- WADA
- Prohibited (S2.3)
Not schedulable in Claritide. Our sources publish no dosing figure for PEG-MGF, so there is nothing to build a schedule from.
Why this tier
FDA’s note on the withdrawn table is unambiguous: it has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration. We publish no dose range as a result. FDA says it will hold an advisory committee meeting on it before the end of February 2027.
What it is
PEG-MGF is a pegylated form of mechano growth factor, sold for muscle and tendon repair. FDA states it has not identified any human exposure data on drug products containing PEG-MGF administered via any route. FDA says it will hold an advisory committee meeting on it before the end of February 2027, and it is named on the WADA Prohibited List as a non-Specified substance.
How it works
Mechano growth factor is a splice variant of insulin-like growth factor 1 that is expressed in muscle in response to mechanical loading and damage, where it is associated with satellite-cell activation and repair. Pegylation, attaching polyethylene glycol, is a standard technique for extending a peptide’s circulating half-life. That is the entire rationale: take a locally acting repair signal and make it last longer systemically. Whether that reproduces the local effect or simply produces prolonged systemic IGF-family signalling is not something anyone has measured in a person.
Commonly researched ranges
Not established in available literature. Our sources describe PEG-MGF without publishing a dosing figure, so Claritide does not print one.
- Cycle guidance
- Not established in available literature
- Goals
- Muscle, Recovery
Where this sits with the FDA
FDA 503A bulks · nomination withdrawn; FDA says it will hold an advisory committee meeting on it before the end of February 2027
Removal from Category 2 is not permission. FDA says it will hold an advisory committee meeting on PEG-MGF before the end of February 2027, alongside GHK-Cu, Melanotan II, cathelicidin LL-37 and dihexa acetate.
Last change · 22 April 2026 · PEG-MGF was among the 12 peptides removed from Category 2, announced 15 April 2026 and effective 22 April 2026.
Primary sourceHow it got here
- 15 April 2026
FDA announced a future Pharmacy Compounding Advisory Committee meeting to discuss PEG-MGF, alongside GHK-Cu, Melanotan II, Cathelicidin LL-37 and dihexa acetate, with its time and place still to be scheduled.
- 22 April 2026
FDA removed 12 peptide bulk substances from Category 2 after the nominators withdrew their nominations. Announced 15 April 2026, effective 22 April 2026.
- 28 February 2027
FDA says its Pharmacy Compounding Advisory Committee will meet before the end of February 2027, on a date not yet set.
An advisory vote is not law. In July 2026 an FDA advisory committee voted in favour of adding several peptides to the 503A bulks list, over the explicit recommendation of FDA’s own scientific reviewers, who recommended against all seven. FDA would still have to write a rule, and it has not proposed one or given a date. None of these compounds is lawfully compoundable today.Note what FDA actually assessed: BPC-157 for ulcerative colitis, TB-500 for wound healing, KPV for wound healing and inflammatory conditions, MOTS-c for obesity and osteoporosis, Epitalon for insomnia, Semax for cerebral ischaemia, migraine and trigeminal neuralgia. Whatever emerges from rulemaking will be scoped to those indications.
WADA status
The 2026 List names "Mechano growth factors (MGFs)" under S2.3, Growth Factors. Non-Specified, which carries a harsher sanction range than S0. Prohibited at all times.
The FDA reclassification has no effect whatsoever on WADA status. PEG-MGF stays S2.3 whether or not it lands on the 503A bulks list.
Mixing recipes our sources document
Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator
Week by week
Not established in available literature.
Side effects
Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for PEG-MGF.
Contraindications and interactions
Do not use if
- Drug-tested competition: PEG-MGF is named on the 2026 WADA Prohibited List under S2.3 as a non-Specified substance, prohibited at all times
Interactions
Not established in available literature.
Absence from this list does NOT mean safety. It means lack of research.
Storage and cost
- Storage
- Our sources publish no vial and diluent pairing or beyond-use window for PEG-MGF.
- Cost
- Not established in available literature
PEG-MGF in full
Limited coverage
PEG-MGF is pegylated mechano growth factor, sold for muscle and tendon repair.
The sentence that defines the record
From FDA's withdrawn table: "FDA has not identified any human exposure data on drug products containing PEG-MGF administered via any route of administration."
That is the same sentence FDA writes for MOTS-c, TB-500, KPV and dihexa. It is stronger than "the evidence is weak": it says nobody has documented a person being exposed to this compound in a way that produced any data at all.
We publish no dose range for PEG-MGF as a result. There is nothing to publish.
What it is meant to be
Mechano growth factor is a splice variant of IGF-1 expressed in muscle in response to loading and damage, associated with satellite-cell activation. Pegylation attaches polyethylene glycol to extend circulating half-life.
The rationale is: take a locally acting repair signal and make it last. Whether that reproduces the local effect, or simply produces prolonged systemic IGF-family signalling with everything that implies, is unmeasured in humans.
Regulatory and anti-doping
PEG-MGF was among the 12 peptides removed from Category 2 effective 22 April 2026, and FDA says it will hold an advisory committee meeting on it before the end of February 2027. Removal is not permission.
For athletes it is unambiguous: the 2026 WADA List names "Mechano growth factors (MGFs)" under S2.3, prohibited at all times and non-Specified, a harsher sanction category than the S0 catch-all.
Sources
- 1FDA · Certain bulk drug substances for use in compounding that may present significant safety risks
- 2FDA · Meeting of the Pharmacy Compounding Advisory Committee, to be held before the end of February 2027, on cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF (content current as of 15 April 2026)
- 3WADA 2026 Prohibited List · S2.3 Growth Factors
Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.